secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-08-04T20:32:44+00:00
Accession:  0001628280-26-052642
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Reports Q3 Fiscal 2026 Revenue of $161M, Up 12% YoY
----------------------------------------------------------

- Revenue from continuing operations was $161M, up 12% year over year; organic growth was 9%.
- Sample Management Solutions revenue rose 14% to $88M; Multiomics revenue rose 10% to $73M.
- Diluted EPS from continuing operations was ($0.03); total diluted EPS was $0.05, compared to ($1.05) a year ago.
- Adjusted EBITDA from continuing operations was $18.5M, with margin of 11.4%.
- Sale of B Medical Systems closed on July 1, 2026; results reported as discontinued operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/0001628280-26-052642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/azta-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer